Comparison among stereotactic body radiation therapy, lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer: a network meta-analysis

立体定向放射治疗、肺叶切除术、肺段切除术和楔形切除术治疗临床I期非小细胞肺癌的比较:一项网络荟萃分析

阅读:1

Abstract

BACKGROUND: Lung resections and stereotactic body radiation therapy (SBRT) are primary treatments for clinical stage I non-small cell lung cancer (NSCLC). The aim of this network meta-analysis is to compare the differences in effectiveness between SBRT and specific lung resections, including lobectomy, segmentectomy, and wedge resection for clinical stage I NSCLC. METHODS: PubMed, EMBASE, Cochrane Library, and the ClinicalTrials.gov registry were searched. Random-effects model was conducted to assess differences in survival outcomes and treatment-related complication incidence between SBRT and three specific lung resections (lobectomy, segmentectomy, wedge resection). Subgroup analyses were performed according to clinical stages, regions, and publication years. RESULTS: A total of 30 studies were enrolled for network meta-analysis. All three lung resections demonstrated superior overall survival (OS) compared with SBRT [lobectomy: hazard ratio (HR) 0.65, 95% confidence interval: 0.53-0.79; segmentectomy: HR 0.64, 95% confidence interval: 0.50-0.82); wedge resection: HR 0.72, 95% confidence interval: 0.55-0.93]. The recurrence-free survival (RFS) of patients in lobectomy and segmentectomy groups was significantly better than that of patients in the SBRT group, with no significant difference between the wedge resection and SBRT groups. Patients with clinical stage IA NSCLC showed no significant difference in OS between SBRT and three lung resections (lobectomy: HR 0.99, 95% confidence interval: 0.85-1.16; segmentectomy: HR 0.98, 95% confidence interval: 0.83-1.16; wedge resection: HR 1.71, 95% confidence interval: 0.91-3.26). CONCLUSIONS: For clinical stage I NSCLC patients, lobectomy and segmentectomy are superior to SBRT. Wedge resection is associated with similar RFS but better OS to SBRT. In clinical stage IA NSCLC, SBRT may provide comparable OS to lung resections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。